

**Prof. Evelina Tacconelli, MD, PhD***Email :evelina.tacconelli@univr.it**Date of birth: 26.11.1967*

**Ruolo:** Professore ordinario di Malattie Infettive c/o Università degli Studi di Verona. Direttore dell'Unità di Malattie Infettive c/o Università di Tübingen, Germania.

**Studi:** Laurea in Medicina e Chirurgia (09/1986 – 07/1992), Specializzazione in Malattie Infettive (09/1992 – 07/1996) c/o Università Cattolica, Roma; Master in Epidemiologia per Operatori Sanitari (09/1997 – 07/1998) c/o Università La Sapienza, Roma.

**Incarichi professionali**

Da Ottobre 2017	Professore Ordinario di Malattie Infettive, Università di Verona
Dal 2013	Professore Ordinario di Malattie Infettive, Università di Tübingen, Germania; Direttore dell'Unità di Malattie Infettive c/o Università di Tübingen, Germania
2013-2017	Direttore della Divisione di Malattie Infettive, Medicina Interna I, Ospedale Universitario di Tübingen, Germania
2003-2007	Docente di Malattie Infettive, BIDMC and Harvard Medical School, Boston, USA
1999 – 2013	Professore Associato di Malattie Infettive, Università Cattolica, Roma
1997-1999	Specialista in Malattie Infettive, Università Cattolica, Roma

**Altri incarichi**

Dal 2009	Education Officer of Infectious Diseases and Clinical Microbiology for the European Society of Clinical Microbiology and Infectious Disease (ESCMID)
Dal 2015	Chair of EUCIC (European Committee of infection Control)
Dal 2017	ESCMID Group for the guidelines for the therapy of multidrug-resistant gram-negative bacteria, Chairman
Dal 2016	ESCMID Group for the guidelines for the decolonisation of multidrug-resistant gram-negative bacteria, Chairman
2010 – 2013	ESCMID Group for guidelines for the control of hospital spreading of multidrug-resistant gram-negative bacteria, Chairman
2012 – 2013	External Affairs Committee of SHEA
Dal 2009	ECDC Consultant for antibiotic stewardship and MDR-gram negative bacteria
Dal 2010	WHO Consultant on antimicrobial resistance and infection control

2008-2012	ISC risk assessment of MRSA group (International Society of Chemotherapy Working Group on MRSA), Chairman
2009-2013	Study Group on Antibiotic Resistance in Hospitalised Patients of SIMIT (Italian Society of Infectious Diseases), Chairman

**7) Aree di interesse:** Epidemiologia ed impatto clinico delle infezioni nosocomiali; antimicrobial stewardship; Infection control e public health.

**8) Autore e co-author di 180 lavori su SCI-JCR e NIH Medline (6849 citazioni, 47 H-index). Di seguito 10 pubblicazioni selezionate:**

1. Tacconelli E, et al. Surveillance for control of antimicrobial resistance. Lancet Infect Dis. Oct 2017, 1-8 **(IF 19.9)**
2. Gladstone BP,.. Tacconelli E. Antimicrobial resistance rates in gram-positive bacteria do not drive glycopeptides use. PLoS One. 2017 Jul 20;12(7):e0181358. **(IF 3.5)**
3. Tacconelli E, et al. Discovery, research and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria. Lancet Infect Dis. 2017**(IF 19.9)**
4. Baur D, ... Tacconelli E. Effect of antibiotic stewardship on the incidence of infection and colonization with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017 Sep;17(9):990-1001. **(IF 19.9)**
5. Tacconelli E, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014 Jan;20 Suppl 1:1-55. **(IF 5.1)**
6. Tacconelli E, et al. Rapid screening tests for meticillin-resistant Staphylococcus aureus at hospital admission: systematic review and meta-analysis. Lancet Infect Dis. 2009 Sep;9(9):546-54. **(IF 19.9)**
7. Tacconelli E, et al. Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agents Chemother. 2009 Oct;53(10):4264-9. **(IF 4.6)**
8. Tacconelli E. Antimicrobial use: risk driver of multidrug resistant microorganisms in healthcare settings. Curr Opin Infect Dis. 2009 Aug;22(4):352-8. **(IF 4.2)**
9. Tacconelli E, et al. Prediction models to identify hospitalized patients at risk of being colonized or infected with multidrug-resistant Acinetobacter baumannii calcoaceticus complex. J Antimicrob Chemother. 2008 Nov;62(5):1130-7. **(IF 5)**
10. Tacconelli E, et al. Preventing the influx of vancomycin-resistant enterococci into health care institutions, by use of a simple validated prediction rule. Clin Infect Dis. 2004 Oct 1;39(7):964-70. **(IF 8.8)**

#### Libri:

- E. Tacconelli, Risk assessment for MRSA in: Gould. Antibiotic policies: fighting resistance, Springer US, 2007 and 2010;
- E. Tacconelli, U. Frank, The Daschner Guide to in-hospital antibiotic therapy, Springer 1-250 1<sup>st</sup> ed. 2009, 2<sup>nd</sup> ed. 2011;
- E. Tacconelli, F. Foschi, M. Pletz, Antibiotic usage and surgical prophylaxis, in Cohen, Principles of Infectious Diseases, Springer 7<sup>th</sup> ed 2015



June, 20, 2018

"Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".

